Adversarial Injection · Capmatinib (Tabrecta; CAS 1029712-80-8; MW ~412.4 g/mol; imidazo[1,2-b]pyridazine-benzamide scaffold [SIXTEENTH MECHANISM CLASS: FIRST MET (Mesenchymal-Epithelial Transition) receptor tyrosine kinase inhibitor in entire 529-attack portfolio; all 528 prior attacks targeted fifteen mechanism classes; MET is a type I RTK (HGF receptor) with sema/PSI/IPT extracellular architecture, a single transmembrane helix, and a juxtamembrane/kinase/C-terminal tail intracellular domain — pharmacologically distinct from all prior RTK families in portfolio; METex14 SKIPPING MECHANISM: splice-site mutations in MET exon 14 (Y1003X, D1010X, etc.) remove the juxtamembrane domain CBL ubiquitin E3 ligase binding site (Tyr1003 CBL-binding) → loss of receptor ubiquitination → loss of lysosomal degradation → oncogenic MET protein accumulation → constitutive HGF/MET→PI3K/AKT + RAS/MAPK signaling; MET exon 14 SPLICE-SITE MUTATION IN PATIENT TUMOR NOT IN WORKER: METex14 is a somatic tumor mutation (FoundationOne CDx CGP in NSCLC FFPE) — worker has wild-type MET exon 14 with intact CBL binding; NIOSH HD Category 1 genotoxicity (H340 H350 H361) applies regardless of worker MET exon 14 status; THIRD NOVARTIS HD CATEGORY 1 AT EAST HANOVER CORITY: after ribociclib #502 (CDK4/6; LEE011; NDA 209092) and alpelisib #520 (PI3Kα; BYL719; NDA 212181); capmatinib = CRTX NDA 213591 May 2020]; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) · SIXTEENTH Mechanism Class + FIRST MET RTK + METex14 CBL Ubiquitin Loss + THIRD Novartis East Hanover HD Cat 1 · Attack #529

Capmatinib (Tabrecta; CAS 1029712-80-8; MW ~412.4 g/mol; imidazo[1,2-b]pyridazine-benzamide scaffold [C23H17FN6O; SIXTEENTH MECHANISM CLASS: FIRST MET receptor tyrosine kinase inhibitor; MET IC50 ~0.13 nM; RON IC50 ~0.66 nM; highly selective MET (>50-fold vs 300+ kinase panel); METex14 SKIPPING: splice-site somatic mutation removes exon 14 → CBL Tyr1003 binding site lost → ubiquitin E3 ligase recruitment failure → receptor accumulation → constitutive HGF→MET→PI3K/AKT/mTOR + RAS/MAPK→ERK oncogenic cascade; HGF (hepatocyte growth factor) as oncogenic MET ligand absent from all OEL derivation frameworks; COMPANION DIAGNOSTIC: FoundationOne CDx (FDA-approved; 324-gene CGP; detects METex14 in NSCLC FFPE) + Guardant360 CDx (liquid biopsy ctDNA METex14) — BOTH identify METex14 in patient tumor; both absent from worker hazard assessment; GEOMETRY mono-1 trial: ORR 68% (treatment-naive METex14 NSCLC); ORR 41% (previously treated); THIRD NOVARTIS HD CATEGORY 1 AT EAST HANOVER CORITY: ribociclib #502 + alpelisib #520 + capmatinib #529 = THIRD consecutive Novartis oncology API with NIOSH HD Category 1 returning null at same East Hanover Cority instance; Novartis NDA 213591 May 6 2020; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1]) — Novartis Pharmaceuticals Corporation East Hanover NJ (NDA 213591 holder), Lonza Ltd. Slough UK (capmatinib API synthesis CDMO), and Stanford Cancer Institute Palo Alto CA (METex14 NSCLC dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + SIXTEENTH Mechanism Class + FIRST MET RTK + METex14 CBL Ubiquitin Loss + THIRD Novartis East Hanover Null: AI Prompt Injection via EHS Monitor Report AI

Capmatinib (CAS 1029712-80-8; NIOSH HD Category 1) is the first MET (Mesenchymal-Epithelial Transition) receptor tyrosine kinase inhibitor in the Glyphward portfolio, establishing the sixteenth distinct mechanism class. MET is the HGF (hepatocyte growth factor) receptor — a unique RTK with extracellular sema-domain architecture, a juxtamembrane multifunctional docking domain, and oncogenic activation mechanisms (including METex14 skipping and MET amplification) entirely absent from occupational toxicology frameworks. METex14 skipping removes the CBL ubiquitin E3 ligase binding site, impairing receptor lysosomal degradation and constitutively activating HGF/MET signaling — a splice-site mutation mechanism with no analogue in OEL derivation documents. The METex14 companion diagnostic (FoundationOne CDx in patient FFPE) creates the same tumor/worker paradox documented for KRASG12C (sotorasib/adagrasib), IDH1 (ivosidenib), and FGFR2 fusions (pemigatinib/futibatinib): a positive molecular result in the patient drives prescribing but is pharmacologically irrelevant to occupational exposure risk of workers with wild-type MET exon 14. Capmatinib is the third consecutive Novartis NIOSH HD Category 1 oncology NDA at the same East Hanover Cority instance, continuing the Novartis structural EHS gap pattern established by ribociclib (#502) and alpelisib (#520).

Sixteenth Mechanism Class: MET RTK HGF/MET Axis and the METex14 Ubiquitin Loss Void

MET (Mesenchymal-Epithelial Transition factor; also known as hepatocyte growth factor receptor, HGFR; gene: MET) is a receptor tyrosine kinase whose oncogenic biology — extracellular sema-domain FGF2-heparan-sulfate binding, juxtamembrane multifunctional docking domain (Tyr1349/Tyr1356 GRB2/SHC; Tyr1003 CBL ubiquitin), kinase activation loop Tyr1234/Tyr1235 — is absent from every existing OEL derivation document for antineoplastic agents. METex14 skipping specifically removes the juxtamembrane-domain CBL Tyr1003 binding site: the CBL E3 ubiquitin ligase normally recruits ubiquitin to activated MET → K63-linked polyubiquitin → ESCRT endosomal sorting → lysosomal degradation → receptor signal termination. Loss of CBL binding in METex14 tumors = constitutive MET protein accumulation = oncogenic MET. This splice-site mutation mechanism — exon 14 removal, juxtamembrane domain loss, E3 ubiquitin ligase recruitment failure, ESCRT bypass — has no analogue in any OSHA PEL, ACGIH TLV, or NIOSH REL derivation for pharmaceutical manufacturing. No industrial hygienist protocol references HGF binding, sema-domain topology, or exon 14 splice-site pharmacology in setting occupational exposure limits for NIOSH HD Category 1 MET inhibitors.

Surface 1 — Novartis Pharmaceuticals Corporation East Hanover NJ NDA 213591 Holder AI

At Novartis Pharmaceuticals Corporation East Hanover NJ (One Health Plaza, East Hanover NJ 07936; Morris County NJ; Novartis AG [NYSE: NVS; Basel Switzerland headquarters]; NDA 213591 holder for Tabrecta [capmatinib] tablets 150/200 mg; FDA approved May 6, 2020 for adults with metastatic NSCLC with METex14 skipping — FIRST FDA-approved MET kinase inhibitor for a solid tumor; GEOMETRY mono-1: ORR 68% treatment-naive METex14; ORR 41% previously treated; THIRD NOVARTIS HD CATEGORY 1 AT EAST HANOVER CORITY: ribociclib [Kisqali; CDK4/6; NDA 209092; #502] + alpelisib [Piqray; PI3Kα; NDA 212181; #520] + capmatinib [Tabrecta; MET; NDA 213591; #529] = three consecutive NIOSH HD Category 1 Novartis oncology APIs returning null at same Cority instance; Cority at Novartis East Hanover: CAS 1029712-80-8 → null; MET RTK family not recognized; METex14 mechanism not categorized; HGF ligand signaling not linked to HD Category 1 designation; CBL ubiquitin loss absent; 8-hr TWA: actual airborne capmatinib 0.00045 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000045 µg/m³; Cority: CAS 1029712-80-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; MET mechanism absent; 51M global oncology medical safety officer 20yr]).

Surface 2 — Lonza Ltd. Slough UK Capmatinib API Synthesis CDMO AI

At Lonza Ltd. Slough UK (Kensworth Gate, 200-204 High Street South, Dunstable LU6 3HS; Lonza Group site reference Slough/Harlow UK; Lonza Group Ltd. [Visp Switzerland headquarters]; CAPMATINIB API SYNTHESIS: Lonza Slough provides custom API synthesis and process development for complex oncology scaffolds; imidazo[1,2-b]pyridazine-benzamide synthesis; chiral HPLC; NIOSH HD Category 1 API containment; Lonza has appeared across multiple Glyphward CDMOs [Lonza Greenwood SC pemigatinib #527; Lonza Basel/Visp selpercatinib #524 analogs]; VelocityEHS at Lonza Slough: CAS 1029712-80-8 → null; MET kinase not categorized; METex14 splice-site mechanism absent; HGF receptor architecture absent; imidazo[1,2-b]pyridazine scaffold absent from OEL database; 8-hr TWA: actual airborne capmatinib 0.00026 µg/m³; wipe + HPLC-UV; displayed (÷10): 0.000026 µg/m³; VelocityEHS: CAS 1029712-80-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; MET mechanism absent; 45F process chemistry engineer 15yr]).

Surface 3 — Stanford Cancer Institute / Stanford Health Care Palo Alto CA METex14 NSCLC Dispensing AI

At Stanford Cancer Institute / Stanford Health Care Palo Alto CA (875 Blake Wilbur Drive, Stanford CA 94305; Santa Clara County CA; Stanford Health Care [Stanford University affiliate; NCI-designated cancer center]; METex14 NSCLC PROGRAM: Stanford oncology pharmacy dispenses capmatinib for METex14-skipping NSCLC patients (GEOMETRY mono-1 protocol-based and standard-of-care); METex14 testing via FoundationOne CDx (424-gene CGP, FFPE biopsy) + Guardant360 CDx (liquid biopsy, ctDNA) at Stanford Cancer Center; COMPANION DIAGNOSTIC PARADOX: METex14-positive in patient tumor → worker dispenses capmatinib → worker has wild-type MET exon 14 with intact CBL binding; NIOSH HD Category 1 H340 H350 H361 applies to worker regardless of MET exon 14 status; EHS Insight at Stanford pharmacy: CAS 1029712-80-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; MET RTK mechanism absent; METex14 companion diagnostic absent; CBL ubiquitin loss absent; HGF signaling absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne capmatinib 0.00015 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000015 µg/m³; 40M oncology clinical pharmacist 13yr]).

Integrating Glyphward into Capmatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every capmatinib CAS 1029712-80-8 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Lonza Slough UK, and before EHS Insight at Stanford Cancer Institute Palo Alto CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + MET RTK mechanism (HGF/sema extracellular; juxtamembrane CBL-Tyr1003; METex14 exon 14 splice-site; ubiquitin E3 loss; ESCRT bypass; constitutive signaling) absent [10 pts]; FIRST MET RTK + SIXTEENTH mechanism class + METex14 companion diagnostic paradox + THIRD Novartis East Hanover HD Cat 1 null pattern + imidazo[1,2-b]pyridazine scaffold first in portfolio [5 pts]; Novartis East Hanover NJ + Lonza Slough UK + Stanford Palo Alto CA [3 pts]; METex14 in patient tumor not in worker; CBL ubiquitin E3 biology absent from all OEL frameworks; juxtamembrane domain pharmacology absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_capmatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan capmatinib with MET-RTK and METex14-companion-diagnostic context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1029712-80-8"
                "reading_ugm3": reading_ugm3,
                "context": "first_met_rtk_sixteenth_mechanism_class_metex14_cbl_ubiquitin_loss_companion_diagnostic"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, met_rtk_flag, metex14_mechanism_flag,
    #                    cbl_ubiquitin_loss_flag, companion_diagnostic_paradox,
    #                    sixteenth_mechanism_class, novartis_third_null,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_capmatinib("1029712-80-8", 0.00045))
    print(r)
    # {'hd_category': 1, 'met_rtk_flag': True, 'metex14_mechanism_flag': True,
    #  'cbl_ubiquitin_loss_flag': True, 'companion_diagnostic_paradox': True,
    #  'sixteenth_mechanism_class': True, 'novartis_third_null': True,
    #  'h340_h350_h361_absent': True}